News
Pharma update: injunction against generic combination of ezetimibe and simvastatin denied
In the interim relief decision of 11 June 2018 (ECLI:NL:RBDHA:2018:6802) in the matter Merck Sharp & Dohme Corp. / Teva Nederland B.V, Pharmachemie B.V. and Centrafarm B.V. the Provisions Judge of the District Court of The Hague rejected the claim of Merck Sharp & Dohme Corp. for an injunction against the distribution of the generic combination
Read more ›
Honourable mentions for BarentsKrans in the Legal 500
This week Legal 500 released their 2018 rankings. As in previous years, BarentsKrans is mentioned several times in this leading, international guide for the legal profession. Again we are beyond proud of these honourable mentions. High performers BarentsKrans is mentioned at nine different practice areas. Employment, Corporate/M&A, EU & Competition, Private equity, Real estate, Commercial Litigation,
Read more ›
Pharma update: tadalafil patent invalidated
The District Court of The Hague has invalidated ICOS’ patent EP 1 173 181 B3 (‘EP ‘181’) claiming a dosage range of tadalafil for the treatment of sexual dysfunction. Icos Corporation (‘Icos’), an Eli Lilly and Company subsidiary, distributes the medicinal product Cialis® containing tadalafil for the treatment of sexual dysfunction in adult men. EP
Read more ›
Chambers Europe 2018 rankings: again splendid results for BarentsKrans
Last month we published the stunning results that BarentsKrans achieved in the Chambers 2018 Global edition. Meanwhile, the Chambers Europe guide has also been published and we would, once again, like to share our Chambers feedback with you. Chambers and Partners publish their rankings annually while comparing 53 jurisdictions across Europe, from Greenland and the United Kingdom to
Read more ›
Chambers Global 2018 rankings: excellent results for BarentsKrans
Chambers Global 2018, the guide that provides a worldwide overview of international practice areas, has just been released. BarentsKrans received several honourable mentions. This year the most noticeable mention is the Corporate / M&A practice group’s first ranking within the Mid-Markets category. Like last year, the Intellectual Property team has been rewarded with a splendid
Read more ›
Marleen van den Horst receives Client Choice award
Each year, Client Choice recognises those law firm partners around the world that stand apart for the excellent client service they provide. Uniquely, these awards survey senior corporate counsel only, with this year’s winners chosen from a pool of more than 2,000 individual client assessments. On February 8 the award for Healthcare & Life Sciences
Read more ›
Pharma update: Indirect infringement of Swiss type claims is possible
In its judgment of 3 November 2017 in the case between Merck Sharp & Dohme (‘MSD’) and Teva, the Dutch Supreme Court ruled (ECLI:NL:HR:2017:2807) that indirect infringement of a ‘Swiss type’ second medical use patent claim is possible. In addition, the Supreme Court found that there is no difference in the scope of protection of second
Read more ›
Generic Pemetrexed Diacid infringes patent Pemetrexed Disodium
In two judgments of 24 October 2017, the Provisions Judge of the District Court in The Hague held that Teva’s and Fresenius Kabi’s generic pemetrexed diacid products infringe EP 1 313 508 (‘EP ‘508’) of Eli Lilly. EP ‘508 relates to the use of pemetrexed disodium in combination with vitamin B12 for the treatment of certain
Read more ›
Pharma update: long-awaited final relief judgment on enforcement second medical use patent
In its final relief judgement of 5 April 2017 in Sun Pharmaceutical Industries (Europe) B.V. (“Sun“) v. Novartis et al. (“Novartis”), the District Court of The Hague ruled that Sun has directly infringed Novartis’ second medical use patent EP 1 296 689 (EP ‘689) which relates to the treatment of osteoporosis. Previously, in its interim
Read more ›
Pharma update: tadalafil patent obvious to Dutch court
On 26 October 2016 the District Court of The Hague held Icos Corporation’s patent for a formulation of tadalafil invalid in proceedings initiated by Actelion Pharmaceutical Inc. In its reasoning, the Court applied the “try and see” test. Icos owns European Patent EP 1 200 092 (EP092) relating to a small-sized-particle formulation of the known
Read more ›
